NeoGenomics Inc (NEO)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $2.07B
Last updated: Nov 17, 2026 at 11:06 AM ET
NeoGenomics Inc (NEO) P/E Ratio & Valuation History
NeoGenomics (NEO) trades at 228.9x trailing earnings and 2.6x sales. Its P/S of 2.6x is below its 5-year median of 2.8x. Its forward P/E is 222.2x. The median P/E across 5 similar companies is 20.5x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 3.0% higher over the next year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 228.9x |
| Forward P/E | 222.2x |
| Price to sales | 2.6x |
| Price to book | 2.6x |
| EV/EBITDA | 71.3x |
| PEG | 2.1 |
| FCF yield | -1.4% |
Historical Medians
Against its 10-year medians, its P/S is 21.2% below 3.3x and its P/B is 16.1% below 3.1x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 2.6x | 2.8x | 3.3x |
| P/B | 2.6x | 1.9x | 3.1x |
Valuation History
Over the 5 of the 10 year ends shown that have a P/E, its P/E ranged from 53.6x in 2016 to 384.6x in 2020. 2020 was the highest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $11.76 | N/A | 2.1x | 1.8x |
| 2024 | $16.48 | N/A | 3.2x | 2.3x |
| 2023 | $16.18 | N/A | 3.4x | 2.2x |
| 2022 | $9.24 | N/A | 2.3x | 1.2x |
| 2021 | $34.12 | N/A | 8.7x | 3.8x |
| 2020 | $53.84 | 384.6x | 13.3x | 8.9x |
| 2019 | $29.25 | 94.4x | 7.4x | 6.2x |
| 2018 | $12.61 | 63.0x | 4.1x | 3.8x |
| 2017 | $8.86 | 68.2x | 2.8x | 3.4x |
| 2016 | $8.57 | 53.6x | 2.7x | 3.6x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About NEO
What is NEO's forward P/E ratio?
NeoGenomics has a forward P/E ratio of 222.2x.
Is NEO stock overvalued?
GNG's valuation label for NEO is Overvalued. Its P/E of 228.9x compares with a median of 20.5x across 5 similar companies.
What is NEO's price to sales ratio?
NeoGenomics has a price to sales ratio of 2.6x.
What is NEO's PEG ratio?
NeoGenomics has a PEG ratio of 2.1.
NEO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts